Pfizer Inc. $PFE Shares Acquired by Sterling Investment Advisors Ltd.

Sterling Investment Advisors Ltd. boosted its position in Pfizer Inc. (NYSE:PFE) by 27.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 124,752 shares of the biopharmaceutical company’s stock after buying an additional 27,192 shares during the quarter. Sterling Investment Advisors Ltd.’s holdings in Pfizer were worth $3,503,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Sigma Planning Corp grew its position in shares of Pfizer by 3.3% in the 1st quarter. Sigma Planning Corp now owns 171,573 shares of the biopharmaceutical company’s stock worth $4,818,000 after acquiring an additional 5,500 shares in the last quarter. Adell Harriman & Carpenter Inc. increased its holdings in shares of Pfizer by 6.7% in the 1st quarter. Adell Harriman & Carpenter Inc. now owns 291,128 shares of the biopharmaceutical company’s stock valued at $8,175,000 after acquiring an additional 18,230 shares during the last quarter. Checchi Capital Advisers LLC raised its position in shares of Pfizer by 24.8% during the 1st quarter. Checchi Capital Advisers LLC now owns 27,927 shares of the biopharmaceutical company’s stock valued at $784,000 after acquiring an additional 5,553 shares in the last quarter. Nwam LLC raised its position in shares of Pfizer by 24.3% during the 1st quarter. Nwam LLC now owns 53,887 shares of the biopharmaceutical company’s stock valued at $1,513,000 after acquiring an additional 10,531 shares in the last quarter. Finally, Maryland State Retirement & Pension System lifted its stake in Pfizer by 0.6% during the first quarter. Maryland State Retirement & Pension System now owns 285,059 shares of the biopharmaceutical company’s stock worth $8,004,000 after purchasing an additional 1,667 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst coverage remains supportive, even after some modest price-target cuts. BMO kept an outperform rating and Guggenheim maintained a buy, suggesting Wall Street still sees upside from current levels. Benzinga analyst update
• Positive Sentiment: Pfizer’s oncology franchise is in focus ahead of Q2 results, with growth from key cancer drugs, biosimilars, and pipeline updates potentially helping offset declines in older medicines. Zacks oncology outlook
• Positive Sentiment: Investors are also encouraged by the long-term case for Pfizer’s Seagen integration, which some analysts argue could improve oncology growth and create durable value versus peers like Amgen. 247WallSt Pfizer vs. Amgen
• Neutral Sentiment: Pfizer’s dividend yield remains unusually high at about 7.1%, which may attract income investors, but it also raises questions about whether the payout reflects slower growth expectations. Motley Fool dividend article
• Negative Sentiment: Near-term earnings expectations are soft, with Wall Street looking for a double-digit decline in profit in the next quarterly report, reinforcing concerns about pressure on Pfizer’s core business. Barchart earnings preview
• Negative Sentiment: Drug-pricing headlines tied to the Trump administration are adding policy uncertainty across big pharma, including Pfizer, even though pipeline strength may ultimately matter more. Motley Fool drug-pricing article

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research reports. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Guggenheim reduced their price target on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and decreased their price target for the company from $32.00 to $28.00 in a report on Monday, July 6th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. Finally, CICC Research began coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.24 on Wednesday. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The business’s fifty day moving average price is $25.28 and its two-hundred day moving average price is $26.18. The firm has a market capitalization of $138.17 billion, a PE ratio of 18.51 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period last year, the business posted $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.